Anzeige
Mehr »
Mittwoch, 04.03.2026 - Börsentäglich über 12.000 News
60.000 USD pro Tonne! Entsteht hier der nächste Gewinner im Antimon-Boom?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 906743 | ISIN: PLAPATR00018 | Ticker-Symbol: 8QM
Stuttgart
04.03.26 | 09:46
5,580 Euro
+6,08 % +0,320
Branche
Maschinenbau
Aktienmarkt
OSTEUROPA
1-Jahres-Chart
APATOR SA Chart 1 Jahr
5-Tage-Chart
APATOR SA 5-Tage-Chart
RealtimeGeldBriefZeit
5,5705,78010:06

Aktueller Chart APATOR Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
APATOR SA-Investoren interessieren sich auch für diese Wertpapiere
ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally 2025 Sales Momentum: ANKTIVA net product revenue increased 20% quarter-over-quarter, with full-year net product revenue of $113 million, representing an approximately 700% increase year-over-year...
► Artikel lesen
ImmunityBio, Inc.: ImmunityBio Expands Access to ANKTIVA in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries Dublin-based subsidiary to support ImmunityBio's distribution...
► Artikel lesen
ImmunityBio, Inc.: ImmunityBio Receives Authorization from the European Commission for ANKTIVA with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ...
► Artikel lesen
Filtronic - Exploiting the growing addressable marketFiltronic's H126 results reflected stable revenues and the ongoing investment in manufacturing, engineering and business development. The company has started H226 with a record order book and efforts...
► Artikel lesen
Filtronic - Another defence winFiltronic has won another material contract with a major European defence prime, with the initial tranche of the contract worth c £7m and the total value of the contract worth £11m over two years. The...
► Artikel lesen
Filtronic - Ka-band development contractFiltronic has been awarded funding of £1.2m by the UK Space Agency's National Space Innovation Programme to develop a high-power Ka-band solid state power amplifier (SSPA). Filtronic has a strong position...
► Artikel lesen